



CIN : U24100DL2011PLC226781

Fabino Life Sciences Ltd.

(An ISO 9001:2015 Certified Company)

November 13, 2023

To,
Listing Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code- 543444

Dear Sir / Madam,

Sub: Outcome of Board Meeting & Submission of Unaudited Financial Results for Half Year ended September 30, 2023

In continuation of our letter dated November 02, 2023 and November 10, 2023, pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors the Company at their meeting held today i.e. November 13, 2023 at Registered Office of the Company, inter alia considered and approved the following;

1. The Unaudited Standalone Financial Results set out in compliance with Accounting Standards (AS) for the Quarter and Half Year ended September 30, 2023 together with Statement of Assets and Liabilities and Statement of Cash Flow.
2. The Unaudited Consolidated Financial Results set out in compliance with Accounting Standards (AS) for the Quarter and Half Year ended September 30, 2023 together with Statement of Assets and Liabilities and Statement of Cash Flow.

Limited Review Report thereon for Standalone and Consolidated Financial Results pursuant to proviso to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed.

The Board Meeting commenced at 2.30 P.M. and concluded at 03:15 P.M.

The aforesaid results are also being disseminated on Company's website at <https://www.fabinolife.com/fabino-ipo/>

You are requested to kindly update above information on your record.

Thanking You,

For, Fabino Life Sciences Limited

Kanchi Gehlot
(Company Secretary and Compliance Officer)





AUDITORS LIMITED REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS OF THE COMPANY FOR THE HALF AND QUARTER YEAR ENDED 30.09.2023 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 AS AMENDED.

**To Board of Directors of
M/s Fabino Life Sciences Limited**

We have reviewed the accompanying statement of unaudited financial results ("the statement") of Fabino Life Sciences Limited ("the Company") for the half ended 30th September 2023 being submitted by the company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 as amended (the "Act"), read with relevant rules issued there under and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations, including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard require that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus it provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR D G M S & CO.

Chartered Accountants

Firm Regn. No. 0112187W

HIREN

JAYANTILAL

MARU

Hiren J Maru

Partner

Membership No. 115279

UDIN: 23115279BGTWLJ3045

Date: 13th November 2023

Place: Mumbai

Digitally signed by HIREN
JAYANTILAL MARU
Date: 2023.11.13 12:40:30
+05'30'

Office Address: Office No. 10, VihangVihar, Opp. Gautam Park, Panchpakhadi, Thane (West) - 400 602, Maharashtra, India.

Cell: +91 9320268900 **Ph.:** 022 4601 2965 / 2545 2965 **Email:** hirenmaru@yahoo.co.uk

FABINO LIFE SCIENCES LIMITED

CIN: U28100DL2011PLC226791

Registered Office: 105, 1ST FLOOR, D - BLOCK, CENTRAL MARKET, PRASADY VIHAR, DELHI - 110005

Statement of Standalone Unaudited Financial Results for the Half Year and Year Ended 30.09.2023

		(Rupees in lakhs)			
Particulars		Half Year Ended		Year Ended	
		30-09-2023	31-03-2023	30-09-2022	31-03-2022
A	Date of start of reporting period	01-04-2023	01-10-2022	01-04-2022	01-04-2022
B	Date of end of reporting period	30-09-2023	31-03-2023	30-09-2022	31-03-2022
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Audited
Part I					
I Revenue From Operations					
	Net sales or Revenue from Operations	93.97	231.79	104.22	336.01
II Other Income					
		0.00	-0.21	2.46	2.25
III Total Revenue (I + II)		93.97	231.57	106.68	338.26
IV Expenses					
	(a) Cost of materials consumed	0.00	0.10	0.03	0.12
	(b) Purchases of stock-in-trade	77.09	141.07	101.67	242.74
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(6.54)	70.47	(18.30)	52.17
	(d) Employee benefit expense	7.79	8.98	10.14	19.13
	(e) Finance Costs	0.09	0.23	0.17	0.40
	(f) Depreciation and amortisation expense	1.20	1.50	3.50	3.17
	(g) Other Expenses	8.07	9.03	10.30	19.33
Total expenses		87.71	231.46	105.50	337.05
V Profit (loss) before Exceptional and Extraordinary		6.26	0.11	1.10	1.21
VI Exceptional Items					
VII Share of Profit/(Loss) of Associates					
VIII Profit (loss) before Tax (VII-VIII)		6.26	0.11	1.10	1.21
X Tax Expense					
	(a) Current Tax	1.61	0.02	0.29	0.31
	(Less) - MAT Credit				
	Current Tax Expense Relating to Prior years				
	(b) Deferred Tax (Asset)/Liabilities	0.03	(0.09)	(0.09)	(0.18)
XI Net Profit/Loss for the period from Continuing Operations (IX-X)		4.62	0.18	0.90	1.00
XII Profit (Loss) from Discontinuing Operations					
XIII Tax Expenses of Discontinuing Operations					
XIV Net Profit (Loss) from Discontinuing Operations after tax (XII-XIII)					
XV Profit (Loss) for the period (XI+XIV)		4.62	0.18	0.90	1.00
XVI Other Comprehensive Income					
	a i) Amount of item that will not be reclassified to profit or loss				
	ii) Income tax relating to items that will not be reclassified to profit or loss				
	b i) Item that will be reclassified to profit or loss				
	ii) Income tax relating to items that will be reclassified to profit or loss				
XVII Total Comprehensive Income					
Total Comprehensive Income [Comprising Profit for the Period (After tax) and Other comprehensive income] (XV+XVII)		4.62	0.18	0.90	1.00
XVIII Details of equity share capital					
	Paid-up equity share capital (Face Value of Rs. 10/- per equity share)	210.00	210.00	210.00	210.00
	Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
XIX Reserves excluding revaluation reserve as per Balance Sheet					
XX Earnings per share (Not Annualized for Half Year and Year ended)					
	(a) Earnings per share - Continuing Operation (Not Annualized for Half Year and Year ended)	0.22	0.01	0.04	0.05
	Basic earnings per share before extraordinary items	0.22	0.01	0.04	0.05
	Diluted earnings per share before extraordinary items	0.22	0.01	0.04	0.05
	(b) Earnings per share Discontinuing Operation (Not Annualized for Half Year and Year ended)				
	Basic earnings per share after extraordinary items				
	Diluted earnings per share after extraordinary items				
	(c) Earnings per share (Not Annualized for Half Year and Year ended)				
	Basic earnings per share before extraordinary items	0.22	0.01	0.04	0.05
	Diluted earnings per share before extraordinary items	0.22	0.01	0.04	0.05

Notes:-

Notes to Standalone Unaudited financials results for the half year ended September 30, 2023.

- 1 The above Unaudited financial results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and taken on record by the Board of Directors at its meeting held on November 10, 2023 after being reviewed by the Audit Committee.
- 2 The company has been listed on SME platform of Bse on 13th January 2022
- 3 The company is engaged in only one business hence no information has been furnished in accordance with AS 17 on "Segment Reporting" issued by the Institute Of Chartered Accountants Of India
- 4 The aforesaid Half yearly Financial Results are also being disseminated on the website of the Company i.e. (bitips://www.fabinolife.com/fabino-ipo/)
- 5 The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable

Date: 19th November 2023
Place: Delhi



Fabino Life Sciences Limited

 Anil Kumar Jais
 Director
 DIN: 00004339

FABINO LIFE SCIENCES LIMITED

REGD. OFFICE : 105, 1ST FLOOR, D - BLOCK, CENTRAL MARKET, PRASHANT VIHAR, DELHI - 110085
CIN: U24100DL2011PLC226781

BALANCE SHEET AS AT 30th September, 2023

(Rupees in Lakhs)

Particulars	Figures as at the end of current reporting period September 2023	Figures as at the end of current reporting period 2023
I. EQUITY AND LIABILITIES		
<u>(1) Shareholder's Funds</u>		
(a) Share Capital	210.00	210.00
(b) Reserves and Surplus	205.57	201.46
(c) Money received against share warrants	-	-
<u>(2) Share Application money pending allotment</u>		
<u>(3) Non-Current Liabilities</u>		
(a) Long-Term Borrowings	48.33	40.61
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long Term Liabilities	4.50	4.50
(d) Long Term Provisions	-	-
<u>(4) Current Liabilities</u>		
(a) Short-Term Borrowings	-	-
(b) Trade Payables	52.85	37.30
-Micro, Small and Medium Enterprises	-	-
-Others	-	-
(c) Other Current Liabilities	5.90	5.09
(d) Short-Term Provisions	2.41	2.11
Total Equity & Liabilities	529.56	501.07
II. ASSETS		
<u>(1) Non-Current Assets</u>		
<u>(a) Fixed Assets</u>		
(i) Tangible Assets	13.68	14.88
(ii) Intangible Assets	-	-
(iii) Capital work-in-progress	-	-
(iv) Intangible Assets under development	-	-
(v) Fixed assets held for sale	-	-
	13.68	14.88
(b) Non-current investments	-	-
(c) Deferred tax Assets (net)	1.11	1.14
(d) Long term loans and advances	-	-
(e) Other non-current assets	7.81	7.81
<u>(2) Current Assets</u>		
(a) Current investments	-	-
(b) Inventories	125.27	118.73
(c) Trade receivables	216.35	252.72
(d) Cash and cash equivalents	38.45	24.25
(e) Short-term loans and advances	121.90	81.54
(f) Other current assets	5.00	-
Total Assets	529.56	501.07

Date: 19th November 2023
Place : Delhi



FOR FABINO LIFE SCIENCES LIMITED
For Fabino Life Sciences Ltd.

(Signature)
Atul Kumar Jain Sign.
Director
DIN: 00004339

FABINO LIFE SCIENCES LIMITED

REGD. OFFICE : 105, 1ST FLOOR, D- BLOCK, CENTRAL MARKET, PRASHANT VIHAR, DELHI - 110085
CIN: U24100DL2011PLC226781

CASH FLOW STATEMENT AS AT 30th September, 2023

(Rupees in lakhs)

Particulars	Figures as at the end of current reporting period September 2023	Figures as at the end of current reporting period 2023
(A) Cash flows from operating activities		
Profit for the year	4.62	1.08
- Finance costs	0.09	0.40
- Income tax Provision	1.61	0.13
<i>Adjustments for non-cash income and expenses:</i>		
- Depreciation & Amortisation	1.20	3.17
- Loss/(Profit) on sale/disposal of Fixed Assets	-	-
<i>Cash flow included in investing activities:</i>		
- Interest Income	-	-
<i>Changes in operating assets and liabilities:</i>		
- Decrease / (Increase) in Inventory	(6.54)	52.17
- Decrease / (Increase) in Trade Receivables	36.37	-109.06
- Decrease / (Increase) in Other Current Assets	(5.00)	
- Decrease / (Increase) in Other Non Current Assets	-	0.62
- Decrease / (Increase) in Short Term loans & Advances	(40.36)	-19.26
- (Decrease) / Increase in Short Term Borrowings	-	
- (Decrease) / Increase in Trade Payables	15.55	3.38
- (Decrease) / Increase in Short Term Provisions	-	0.00
- (Decrease) / Increase in Other Current Liabilities	0.63	0.85
Cash generated from operations	8.17	(66.51)
Income tax paid	(1.61)	-1.01
Net cash from operating activities	6.56	(67.52)
(B) Cash flows from Investing activities		
Sale of Fixed Assets	-	-
Interest received / (Paid)	(0.09)	-0.40
Purchase of Fixed Assets	-	-0.67
Net cash from investing activities	(0.09)	(1.07)
(C) Cash flows from financing activities		
Proceeds from Share Capital	-	-
Proceeds/(Repayment) from Long-term borrowings	7.72	35.96
Proceeds/(Repayment) of Other Long Current liabilities	-	-2.00
Net cash from financing activities	7.72	33.96
Net increase / (decrease) in cash and cash equivalents	14.19	(34.63)
Cash and cash equivalents at the beginning of year	24.25	58.89
Cash and cash equivalents at the end of year	38.45	24.25

For Fabino Life Sciences Limited



Atul Kumar Jain
Director/ Auth. Sign.
DIN: 00004339

Date: 10th November 2023
Place : Delhi



AUDITORS LIMITED REVIEW REPORT ON UNAUDITED CONSOLIDATED FINANCIAL RESULT OF THE COMPANY FOR THE HALF YEAR ENDED 30.09.2023 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 AS AMENDED.

To Board of Directors of

M/s Fabino Life Sciences Limited

We have reviewed the accompanying statement of unaudited Consolidated financial results ("the statement") of Holding Company FABINO LIFE SCIENCES LIMITED ("the Company") for the half year ended 30th September 2023 and its Subsidiary Company UPENDER METAPLAST PRIVATE LIMITED for the half year ended 30th September 2023 being submitted by the company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. This Statement is the responsibility of the company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standards require that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus it provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR D G M S & CO.

Chartered Accountants

Firm Regn. No. 0112187W

HIREN

JAYANTILAL

MARU

Hiren J Maru

Partner

Membership No. 115279

UDIN: 23115279BGTWLK8373

Digitally signed by
HIREN JAYANTILAL
MARU
Date: 2023.11.13
12:42:50 +05'30'

Date: 13th November 2023

Place: Mumbai

Office Address: Office No. 10, VihangVihar, Opp. Gautam Park, Panchpakhadi, Thane (West) - 400 602, Maharashtra, India.

Cell: +91 9320268900 **Ph.:** 022 4601 2965 / 2545 2965 **Email:** hirenmaru@yahoo.co.uk

FABINO LIFE SCIENCES LIMITED

CIN: U74100DI2011PLC226781

Registered Office: 105, 1ST FLOOR, D - BLOCK, CENTRAL MARKET, PRASHANT VIHAR, DELHI - 110085

Statement of Consolidated Unaudited Financial Results for the Half Year and Year Ended 30.09.2023

(Rupees in Lakhs)

	Particulars	30-09-2023
A	Date of start of reporting period	01-01-2023
B	Date of end of reporting period	30-09-2023
C	Whether results are audited or unaudited	Unaudited
Part I		
I	Revenue From Operations	
	Net sales or Revenue from Operations	1286.12
II	Other Income	1.05
III	Total Revenue (I + II)	1,287.17
IV	Expenses	
(a)	Cost of materials consumed	0.00
(b)	Purchases of stock-in-trade	1263.93
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(24.16)
(d)	Employee benefit expense	0.59
(e)	Finance Costs	0.39
(f)	Depreciation and amortisation expense	1.20
(g)	Other Expenses	25.37
	Total expenses	1,275.32
V	Profit (loss) before Exceptional and Extraordinary Items	11.85
VI	Exceptional Items	
VII	Share of Profit/(Loss) of Associates	
VIII	Profit (loss) before Tax (VI-VIII)	11.85
X	Tax Expense	
(a)	Current Tax	3.01
	(Less):- MAT Credit	
	Current Tax Expense Relating to Prior years	
(b)	Deferred Tax (Asset)/Liabilities	0.03
XI	Net Profit/Loss for the period from Continuing Operations (IX-X)	0.80
XII	Profit (Loss) from Discontinuing Operations	
XIII	Tax Expenses of Discontinuing Operations	
XIV	Net Profit (Loss) from Discontinuing Operations after tax (XII-XIII)	-
XV	Profit (Loss) for the period (XI+XIV)	0.80
XVI	Other Comprehensive Income	
	a. i). Amount of item that will not be reclassified to profit or loss	
	ii). Income tax relating to items that will not be reclassified to profit or loss	
	b. i). Item that will be reclassified to profit or loss	
	ii). Income tax relating to items that will be reclassified to profit or loss	
XVII	Total Comprehensive Income	-
	Total Comprehensive Income (Comprising Profit for the Period (After tax) and Other comprehensive Income) (XV+XVII)	0.80
XVIII	Details of equity share capital	
	Paid-up equity share capital (Face Value of Rs. 10/- per equity share)	210.00
	Face value of equity share capital (Per Share)	Rs. 10/-
XIX	Reserves excluding revaluation reserve as per Balance Sheet	
XX	Earnings per share (Not Annualized for Half Year and Year ended)	0.42
(a)	Earnings per share Continuing Operation (Not Annualised for Half Year and Year ended)	
	Basic earnings per share before extraordinary items	0.42
	Diluted earnings per share before extraordinary items	0.42
(b)	Earnings per share Discontinuing Operation (Not Annualised for Half Year and Year ended)	
	Basic earnings per share after extraordinary items	-
	Diluted earnings per share after extraordinary items	-
(c)	Earnings per share (Not Annualised for Half Year and Year ended)	
	Basic earnings per share before extraordinary items	0.42
	Diluted earnings per share before extraordinary items	0.42

Notes:-

Notes to Standalone Unaudited financials results for the half year ended September 30, 2023.

- 1 The above Unaudited financial results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and taken on record by the Board of Directors at its meeting held on November 10, 2023 after being reviewed by the Audit Committee.
- 2 The company has been listed on SME platform of Bse on 13th January 2022.
- 3 The company is engaged in only one business hence no information has been furnished in accordance with AS 17 on "Segment Reporting" issued by the Institute Of Chartered Accountants Of India
- 4 The aforesaid Half yearly Financial Results are also being disseminated on the website of the Company i.e. (<https://www.fabinolife.com>)
- 5 This being first consolidated result comparative figures of previous periods are not given.

Date :- 13th November 2023
Place :- Delhi



For Fabino Life Sciences Ltd.
(Signature)
Director/Auth. Sign.
DIN: 00004339

FABINO LIFE SCIENCES LIMITED

REGD. OFFICE : 105, 1ST FLOOR, D - BLOCK, CENTRAL MARKET, PRASHANT VIHAR, DELHI - 110085
CIN: U24100DL2011PLC226781

Consolidated Balance Sheet as at 30th September 2023

(Rupees in Lakhs)

Particulars	Figures as at the end of current reporting period September 2023
I. EQUITY AND LIABILITIES	
<u>(1) Shareholder's Funds</u>	
(a) Share Capital	210.00
(b) Reserves and Surplus	209.75
(c) Money received against share warrants	-
<u>(2) Share Application money pending allotment</u>	
<u>(3) Non-Current Liabilities</u>	
(a) Long-Term Borrowings	109.78
(b) Deferred Tax Liabilities (Net)	-
(c) Other Long Term Liabilities	4.50
(d) Long Term Provisions	-
<u>(4) Current Liabilities</u>	
(a) Short-Term Borrowings	-
(b) Trade Payables	247.34
-Micro, Small and Medium Enterprises	-
-Others	-
(c) Other Current Liabilities	5.95
(d) Short-Term Provisions	3.81
Total Equity & Liabilities	791.14
II. ASSETS	
<u>(1) Non-Current Assets</u>	
<u>(a) Fixed Assets</u>	
(i) Tangible Assets	13.68
(ii) Intangible Assets	-
(iii) Capital work-in-progress	-
(iv) Intangible Assets under development	-
(v) Fixed assets held for sale	-
(b) Non-current investments	13.68
(c) Deferred tax Assets (net)	1.11
(c) Long term loans and advances	-
(d) Other non-current assets	7.81
<u>(2) Current Assets</u>	
(a) Current investments	-
(b) Inventories	142.89
(c) Trade receivables	436.31
(d) Cash and cash equivalents	101.73
(e) Short-term loans and advances	87.61
(f) Other current assets	-
Total Assets	791.14



Date: 19th November 2023
Place: Delhi

FOR FABINO LIFE SCIENCES LIMITED
For Fabino Life Sciences Ltd.

Atul Kumar Jain
Atul Kumar Jain, Sign.
Director
DIN: 00004339

FABINO LIFE SCIENCES LIMITEDREGD. OFFICE : 105, 1ST FLOOR, D- BLOCK, CENTRAL MARKET, PRASHANT VIHAR, DELHI - 110085
CIN: U24100DL2011PLC226781


Consolidated Cash Flow Statement as at 30th September 2023

(Rupees in lakhs)

Particulars	Figures as at the end of current reporting period September 2023
(A) Cash flows from operating activities	
Profit for the year	8.80
- Finance costs	0.39
- Income tax Provision	3.04
Adjustments for non-cash income and expenses:	
- Depreciation & Amortisation	1.20
- Loss/(Profit) on sale/disposal of Fixed Assets	-
Cash flow included in investing activities:	
- Interest Income	-
Changes in operating assets and liabilities:	
- Decrease / (Increase) in Inventory	(24.16)
- Decrease / (Increase) in Trade Receivables	(183.59)
- Decrease / (Increase) in Other Current Assets	-
- Decrease / (Increase) in Other Non Current Assets	-
- Decrease / (Increase) in Short Term loans & Advances	(6.06)
- (Decrease) / Increase in Short Term Borrowings	-
- (Decrease) / Increase in Trade Payables	210.04
- (Decrease) / Increase in Other Current Liabilities	0.65
Cash generated from operations	10.31
Income tax paid	(1.61)
Net cash from operating activities	8.70
(B) Cash flows from investing activities	
Sale of Fixed Assets	-
Interest received / (Paid)	(0.39)
Purchase of Fixed Assets	-
Net cash from investing activities	(0.39)
(C) Cash flows from financing activities	
Proceeds from Share Capital	-
Proceeds/(Repayment) from Long-term borrowings	69.18
Proceeds/(Repayment) of Other Long Current liabilities	-
Net cash from financing activities	69.18
Net increase / (decrease) in cash and cash equivalents	77.48
Cash and cash equivalents at the beginning of year	24.25
Cash and cash equivalents at the end of year	101.73

Date: 19th November 2023
Place : Delhi

For FABINO LIFE SCIENCES LIMITED


Atul Kumar Jain, Sign.
Director
DIN: 00004339